Oxford Immunotec Global PLC (OXFD) Trading Up 3.7%
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) were up 3.7% during trading on Tuesday . The stock traded as high as $9.80 and last traded at $9.62, with a volume of 174,175 shares changing hands. The stock had previously closed at $9.28.
Several analysts have commented on OXFD shares. Zacks Investment Research raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. BTIG Research reiterated a “buy” rating and set a $17.00 target price on shares of Oxford Immunotec Global PLC in a research report on Monday, June 27th. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Sunday, June 26th.
The stock has a 50-day moving average of $8.87 and a 200-day moving average of $9.73. The firm’s market cap is $212.37 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. The business had revenue of $19.20 million for the quarter, compared to the consensus estimate of $18.10 million. During the same quarter last year, the firm posted ($0.33) EPS. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. On average, equities analysts forecast that Oxford Immunotec Global PLC will post ($1.28) earnings per share for the current fiscal year.
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.